Compare ODV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODV | CDNA |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | ODV | CDNA |
|---|---|---|
| Price | $3.04 | $16.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $27.33 |
| AVG Volume (30 Days) | ★ 2.9M | 520.3K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $160.81 | $16.01 |
| Revenue Next Year | $60.22 | $11.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $1.36 | $10.96 |
| 52 Week High | $4.80 | $21.49 |
| Indicator | ODV | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 35.90 | 36.38 |
| Support Level | $2.87 | $14.09 |
| Resistance Level | $3.35 | $17.09 |
| Average True Range (ATR) | 0.26 | 0.73 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 16.56 | 4.10 |
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.